GE Healthcare will exclusively distribute under the ULTA brand a new range of microfiltration cartridges and disposable filters from Parker domnick hunter for biopharmaceutical manufacturing. The companies also entered into a joint technology development agreement.

As part of an R&D collaboration, Invitrogen will contribute its PD Direct media and cell line development expertise and Viropro will contribute its protein production expertise, enabling third-party technologies to be prescreened against Invitrogen cell culture products.

Under a multiyear joint R&D program, VisEn Medical will work with Merck & Co. to develop and apply a range of fluorescence imaging agents for real-time imaging of key disease biomarkers in vivo. The agreement expands the companies’ current collaboration.

Matrix Innovation appointed Activotec the European distributor for its resins and supported reagents.

Immunicon and Kreatech Biotechnology BV entered into an exclusive cross licensing agreement that will allow Immunicon to sell Kreatech products in North America.

Promega and the Chinese Academy of Sciences’ Guangzhou Institute of Biomedicine and Health will co-develop compound profiling solutions for small molecules and traditional Chinese medicine drug screening.

ThromboGenics exclusively licensed its technology for the production of stem cell culture medium to Millipore, whose Chemicon division has marketed it as RESGRO since 2005.

Transgenomic appointed Frank R. Witney, PhD, to its Board in April. He is president and CEO of Panomics.

Sigma-Aldrich will market and exclusively distribute ChiroSolve’s ChiroSolv kits, which enable the rapid screening of chiral resolving agents and solvents for the classical resolution of enantiomers.

Assay Designs named Dan Calvo president and CEO. He was previously president and CEO of Cellomics.

ChanTest appointed Cambridge BioScience as its European distributor.

Techne promoted Richard A. Krzyzek, PhD, to vice president of Research for its Biotechnology Division.